Streetbeat News

Regulatory

BBJP

DXJ

EWJ

The Bank of Japan has decided to keep its interest rate unchanged at 0.25%. This decision may impact Japanese-focused ETFs such as BBJP, DXJ, and EWJ, which are traded in the US markets.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 5:28 am

COIN

HOOD

META

MSFT

SMCI

Meta, Microsoft, Robinhood, Super Micro, and Coinbase are in focus due to recent earnings reports and other developments. Meta and Microsoft beat earnings expectations, while Robinhood met earnings but missed revenue estimates. Super Micro's stock plunged due to auditor resignation, and Coinbase missed revenue estimates.

Portfolio Pulse from Benzinga Neuro

October 31, 2024 | 2:31 am

MRMD

MariMed Inc. is expanding its cannabis operations into Missouri and increasing capacity in Illinois. Missouri will be the sixth state for MariMed, with plans to launch products by late November. Illinois is a key market, contributing significantly to sales, and MariMed is investing in a new cultivation site there.

Portfolio Pulse from Nicolás Jose Rodriguez

October 31, 2024 | 2:17 am

KDLY

The Benzinga Cannabis Capital Conference discussed challenges in the cannabis market, focusing on patient-centric care, regulatory hurdles, and the friction between medical and adult-use markets. Key figures emphasized the importance of education, advocacy, and maintaining medical integrity in the evolving cannabis landscape.

Portfolio Pulse from Rolando García

October 31, 2024 | 1:30 am

STBX

Trading for STBX has been halted as of 7:50:00 p.m. ET due to pending news. Investors should stay alert for updates that could impact the stock's price.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:50 pm

IRTC

iRhythm Technologies has received FDA 510(k) clearance for design modifications to its Zio AT device, which is used for ambulatory Mobile Cardiac Telemetry (MCT) monitoring. The enhancements will be available in 2025.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 9:16 pm

WVE

Wave Life Sciences is advancing its pipeline with WVE-007 set for clinical trials in 2025 and new RNA editing programs targeting cardiometabolic diseases. The company plans to have five programs in the clinic by 2026, showcasing its innovative platform.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 9:12 pm

ME

23andMe has regained compliance with Nasdaq's minimum closing bid price requirement, ensuring its continued listing on the exchange.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 9:11 pm

NJR

New Jersey Natural Gas has received approval from the New Jersey Board of Public Utilities for the next generation of its SAVEGREEN program, which focuses on energy-efficiency solutions and emissions reduction for residential and commercial customers.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:57 pm

AZTA

Azenta, Inc. (NASDAQ:AZTA) has launched a long-read Whole Genome Sequencing test for clinical applications, becoming the first commercial provider to obtain regulatory approval for this test in the US. This test, using PacBio's Revio sequencer, offers more accurate detection of genetic variants in complex genomic regions, aiding in the diagnosis and treatment of rare diseases.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:48 pm